Eli Lilly to join lawsuit over GLP-1 shortage
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15,
Eli Lilly to join lawsuit over GLP-1 shortage: 4 things to know
Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow compounding pharmacies to continue selling unapproved versions of the drugs, according to court documents obtained by Becker's .
Shares of Eli Lilly & Co. LLY inched 0.50% higher to $781.98 Friday, on what proved to be an all-around positive trading ...
LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
MORF-057 is under development for the treatment of autoimmune disorders including ulcerative colitis, Crohn's disease and eosinophilic esophagitis. It is administered orally. It is developed based on ...
Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback